Tenofovir disoproxil fumarate (Viread) recently gained accelerated FDA approval. It is the first member of a new antiretroviral class and also the first antiretroviral approved on the basis of efficacy trials conducted almost exclusively in treatment-experienced patients. This Focus article reviews these studies and considers how other pending and planned trials may refine tenofovir's role.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Tenofovir: The first nucleotide reverse transcriptase inhibitor for treatment of patients with HIV-1 infection

Newsletter